Scores on the PsAQoL, HAQ and Skindex-17 at first and second assessment.

<p>PsAQoL, psoriatic arthritis quality of life; HAQ, health assessment questionnaire; Skin-17, Skindex-17; N, number of patients.</p

Bland-Altman plot PsAQoL.

<p>Difference between the 1^st and 2^nd PsAQoL plotted against the mean of both assessments. PsAQoL, Psoriatic Arthritis Quality of Life; LOA, limits of agreement; CI, confidence interval.</p

Characteristics of the psoriatic arthritis (PsA) study population.

<p>Data obtained from self-reports.</p>A<p> = responders 1^st series of questionnaires;</p>B<p> = 1^st series PsAQoL complete; used for internal con- sistency assessment;</p>C<p> = 1^st and 2^nd series PsAQoL complete; used for calculating test-retest reliability;</p>D<p> = 1^st series PsAQoL, HAQ and Skindex complete; used for convergent validity analyses.</p><p>PsA, psoriatic arthritis; n, number; y, years; SD, standard deviation; DMARD, disease-modifying antirheumatic drugs; anti-TNFα, anti-tumor necrosis factor α; NSAID, non-steroidal anti- inflammatory drug; PsAQoL, psoriatic arthrtitis quality of life; HAQ, health assessement questionnaire.</p

Convergent validity of the PsAQoL.

<p>PsAQoL, psoriatic arthritis quality of life; HAQ, health assessment questionnaire; Skin-17, Skindex-17.</p>*<p>P<0.01.</p

Baseline characteristics of included AS patients.

<p>Baseline characteristics of included AS patients.</p

GEE estimated mean 2-year spinal radiographic progression rates, stratified for baseline risk factors.

<p>GEE estimated mean 2-year spinal radiographic progression rates, stratified for baseline risk factors.</p

Associations between baseline characteristics and spinal radiographic damage over time.

<p>Associations between baseline characteristics and spinal radiographic damage over time.</p

GEE estimated mean 2-year spinal radiographic progression rates over time of AS patients with multiple risk factors.

<p>GEE estimated mean 2-year spinal radiographic progression rates over time of AS patients with multiple risk factors.</p

Changes in ANCA production over time.

<p>Changes in ANCA production over time.</p

<i>In vitro</i> total and PR3-ANCA specific IgG production.

<p>Levels of <b>A)</b> total IgG and <b>B)</b> PR3-ANCA specific IgG production were determined in <i>in vitro</i> culture supernatant samples from 84 GPA patients and 32 healthy controls at time of inclusion. <b>C-D)</b> The GPA patients were divided based on future relapse. Results at time of inclusion from patients with and without relapse during follow-up and the last sample taken before relapse are depicted. The PR3-ANCA IgG levels in healthy controls were very low and considered to be negative. The dashed line represents the positive cut-off, based on the mean of the healthy control samples + 3 times the standard deviation. Horizontal lines represent median values. *p<0.05. **p<0.01.</p